Drugs for Parkinson's Disease
November 20, 2017 (Issue: 1534)
The motor symptoms of Parkinson's disease (PD) are
caused primarily by degeneration of dopaminergic
neurons in the substantia nigra. The nonmotor
symptoms of the disease are thought to be caused by
degeneration of other neurotransmitter systems.
- Parcopa: a rapidly dissolving formulation of carbidopa/levodopa. Med Lett Drugs Ther 2005; 47:12.
- R Pahwa et al. Randomized trial of IPX066, carbidopa/levodopa extended release, in early Parkinson's disease. Parkinsonism Relat Disord 2014; 20:142.
- Carbidopa/levodopa extended-release capsules (Rytary). Med Lett Drugs Ther 2015; 57:59.
- CW Olanow et al. Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study. Lancet Neurol 2014; 13:141.
- In brief: Duopa – a carbidopa/levodopa enteral suspension for Parkinson's disease. Med Lett Drugs Ther 2015; 57:112.
- HD Weiss and L Marsh. Impulse control disorders and compulsive behaviors associated with dopaminergic therapies in Parkinson disease. Neurol Clin Pract 2012; 2:267.
- KM Biglan et al. Risk factors for somnolence, edema, and hallucinations in early Parkinson disease. Neurology 2007; 69:187.
- HA Teive and RP Munhoz. Rotigotine-induced nail dyschromia in a patient with Parkinson's disease. Neurology 2011; 76:1605.
- MJ Nirenberg. Dopamine agonist withdrawal syndrome: implications for patient care. Drugs Aging 2013; 30:587.
- Apomorphine (Apokyn) for Parkinson's disease. Med Lett Drugs Ther 2005; 47:7.
- SZ Marsala et al. A systematic review of catechol-O-methyltransferase inhibitors: efficacy and safety in clinical practice. Clin Neuropharmacol 2012; 35:185.
- Rasagiline (Azilect) for Parkinson's disease. Med Lett Drugs Ther 2006; 48:97.
- LW Elmer. Rasagiline adjunct therapy in patients with Parkinson's disease: post hoc analyses of the PRESTO and LARGO trials. Parkinsonism Relat Disord 2013;19:930.
- CW Olanow et al. A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N Engl J Med 2009; 361:1268.
- O Rascol et al. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial. Lancet 2005; 365:947.
- AH Schapira et al. Assessment of safety and efficacy of safinamide as a levodopa adjunct in patients with Parkinson disease and motor fluctuations: a randomized clinical trial. JAMA Neurol 2017; 74:216.
- Safinamide (Xadago) for Parkinson's Disease. Med Lett Drugs Ther 2017; 59:151.
- Extended-release amantadine (Gocovri) for dyskinesia in Parkinson's disease. Med Lett Drugs Ther 2017 Nov 8 (epub).
- RL Woosley and KA Romero. QT drugs list. Available at www.crediblemeds.org. Accessed November 9, 2017.
- D Athauda et al. Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial. Lancet 2017; 390:1664.
- F Pagan et al. Nilotinib effects in Parkinson's disease and dementia with Lewy bodies. J Parkinsons Dis 2016; 6:503.
- Deep brain stimulation for Parkinson's disease with early motor complications. Med Lett Drugs Ther 2013; 55:81.
- G Suarez-Cedeno et al. Earlier intervention with deep brain stimulation for Parkinson's disease. Parkinsons Dis 2017 Aug 16 (epub).
- MS Okun. Deep-brain stimulation for Parkinson's disease. N Engl J Med 2012; 367:1529.
- FM Weaver et al. Bilateral deep brain stimulation vs best medical therapy for patients with advanced Parkinson disease: a randomized controlled trial. JAMA 2009; 301:63.
- KA Follett et al. Pallidal versus subthalamic deep-brain stimulation for Parkinson's disease. N Engl J Med 2010; 362:2077.
- WM Schuepbach et al. Neurostimulation for Parkinson's disease with early motor complications. N Engl J Med 2013; 368:610.
- M Lauzé et al. The effects of physical activity in Parkinson's disease: a review. J Parkinsons Dis 2016; 6:685.
- E Bomasang-Layno et al. Antidepressive treatments for Parkinson's disease: a systematic review and meta-analysis. Parkinsonism Relat Disord 2015; 21: 833.
- Pimavanserin (Nuplazid) for Parkinson's disease psychosis. Med Lett Drugs Ther 2016; 58:74.
- J Cummings et al. Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial. Lancet 2014; 383:533.
- Inhibitors and inducers of CYP enzymes and p-glycoprotein. Med Lett Drugs Ther 2017 September 18 (epub). Available at: medicalletter.org/downloads/CYP_PGP_Tables.pdf. Accessed November 9, 2017.
- Drugs for cognitive loss and dementia. Med Lett Drugs Ther 2017; 59:155.
- Extended-release amantadine (Osmolex ER) for Parkinson's disease. Med Lett Drugs Ther 2018; 60 (in press).
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.
Would you like to read the rest of this issue? Gain access below.
Subscribe
Subscriptions to
The Medical Letter on Drugs and Therapeutics include:
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App
- FREE online per issue CME/CE
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
